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OBJECTIVES The purpose of the present study was to measure absolute concentrations of phosphocreatine
(PCr) and adenosine triphosphate (ATP) in normal, hypertrophied, and failing human heart.
BACKGROUND Conflicting evidence exists on the extent of changes of high-energy phosphate metabolites in
hypertrophied and failing human heart. Previous reports using phosphorus-31 magnetic
resonance spectroscopy (31P-MRS) have quantified metabolites in relative terms only.
However, this analysis cannot detect simultaneous reductions.
METHODS Four groups of subjects (n 10 each), were studied: volunteers and patients with hypertensive
heart disease (HHD), aortic stenosis, and dilated cardiomyopathy (DCM). Left ventricular
(LV) function and mass were measured by cine magnetic resonance imaging. Absolute and
relative concentrations of PCr and ATP were determined by 31P-MRS with spatial
localization with optimum pointspread function.
RESULTS Left ventricular ejection fraction remained normal in HHD and aortic stenosis, but was
severely reduced to 18% in DCM; LV mass was increased by 55%, 79%, and 68% respectively.
In volunteers, PCr and ATP concentrations were 8.82  1.30 mmol/kg wet weight and 5.69
 1.02 mmol/kg wet weight, and the PCr/ATP ratio was 1.59  0.33. High-energy
phosphate levels were unaltered in HHD. In aortic stenosis, PCr was decreased by 28%,
whereas ATP remained constant. In DCM, PCr was reduced by 51%, ATP by 35%, and
reduction of the PCr/ATP ratio by 25% was of borderline significance (p 0.06). Significant
correlations were observed among energetic and functional variables, with the closest relations
for PCr.
CONCLUSIONS In human heart failure due to DCM, both PCr and ATP are significantly reduced. Ratios of
PCr to ATP underestimate changes of high-energy phosphate levels. (J Am Coll Cardiol
2002;40:1267–74) © 2002 by the American College of Cardiology Foundation
In normal myocardium, the concentrations of the high-
energy phosphate compounds adenosine triphosphate
(ATP) and phosphocreatine (PCr) are tightly controlled
over a range of performance, because ATP production by
mitochondrial oxidative phosphorylation is closely coupled
to ATP utilization by cytosolic adenosine triphosphatases
(1). Adenosine triphosphate is the direct energy source for
energy-consuming reactions in the cell, while PCr acts as an
energy storage compound, and, in addition, as an energy
transport molecule in the “creatine kinase-PCr energy
shuttle” (2). A number of experimental studies have dem-
onstrated that high-energy phosphate metabolism is de-
ranged in hypertrophied and failing myocardium (see [3,4]
for a review). Previous clinical studies using phosphorus-31
magnetic resonance spectroscopy (31P-MRS) to measure
PCr/ATP ratios in human myocardium (5–16) have shown
that this ratio is reduced in hypertrophied (16) and, even
more so, in failing human myocardium (7,9,11). However,
the PCr/ATP ratio is only an indirect measure of myocar-
dial energetics, because two mechanisms can independently
lead to its reduction (see [4] for review): 1) imbalance of
myocardial oxygen supply and demand (i.e., ischemia) (17),
and 2) reduction of the total creatine pool, a phenomenon
known to occur in heart failure (18,19). Furthermore,
simultaneous decreases of both PCr and ATP remain
undetected when PCr/ATP ratios are used to estimate the
energetic state of the injured heart.
More recently, measurement of absolute concentrations
of high-energy phosphate metabolites in human heart has
become feasible (20,21). We have previously reported on a
new method for absolute quantification of myocardial high-
energy phosphate concentrations, 31P-MRS with spatial
localization with optimum pointspread function (SLOOP)
(22). This method is based on a three-dimensional model
that takes into account anatomic compartments determined
from segmentation of 1H magnetic resonance images, B1
field maps, flip angles, and concentration calibrations.
In the present report, we employed the new tool of
31P-SLOOP MRS to measure absolute concentrations of
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myocardial high-energy phosphate metabolites in normal,
hypertrophied, and failing myocardium. Our hypothesis was
that absolute concentrations of ATP and PCr are reduced in
hypertrophied and failing human myocardium and that,
therefore, PCr/ATP ratios underestimate the true extent of
energetic imbalance. Preliminary accounts of this work have
appeared (23,24).
METHODS
Volunteers. The control group consisted of 10 age-
matched, healthy volunteers (6 male, 4 female, age range 31
to 83 years, mean 59.2 14.9 years) with no history of heart
disease and normal cardiac function as measured by mag-
netic resonance imaging (MRI). Another group of 4 healthy
volunteers (3 female, mean age 27.8  4.3 years) had a
repeated examination by MRS to determine intrasubject
variability of the MRS measurement method (SLOOP).
Patients. Three evenly sized groups of patients were stud-
ied. There were no significant differences for height and
weight among the patient groups. Ten patients had hyper-
tensive heart disease (HHD) (7 male, 3 female, age range 39
to 73 years, mean 60  11 years). Inclusion criteria were a
history of hypertension for more than two years and a
significant (more than two standard deviations above the
mean value of the volunteer group) increase of left ventric-
ular (LV) mass, as determined by MRI. Left ventricular
ejection fraction (EF) was normal, and none of the patients
complained of shortness of breath (New York Heart Asso-
ciation [NYHA] functional class 0). Ten patients had aortic
valve stenosis (6 male, 4 female, age range 43 to 82 years,
mean 67.6  10.9 years). Inclusion criteria were severe
aortic stenosis (aortic valve area 0.70 cm2) and planned
surgical valve replacement. Left ventricular EF in all pa-
tients was40%. Of 10 patients, 3 had mild (grade I) aortic
regurgitation. Seven patients were in NYHA functional
class II and three patients in NYHA functional class III.
Ten patients had dilated cardiomyopathy (DCM) (6 male,
4 female, age range 32 to 68 years, mean 55.3 11.2 years).
Inclusion criterion was reduction of LV EF 40%, as
determined by cine MRI. One patient was in NYHA
functional class II, and nine patients were in NYHA
functional class III. Ischemic heart disease was ruled out in
all groups by cardiac catheterization.
None of the patients had a pacemaker, a history of metal
fragments, implants, or vascular clips, severe arrhythmias,
unstable angina pectoris, or claustrophobia. Written, in-
formed consent was obtained from all patients and volun-
teers after the nature of the examination was fully explained,
and the study was approved by the local ethics committee.
MRI. Magnetic resonance imaging was performed on a
1.5-T scanner (Magnetom VISION, Siemens, Erlangen,
Germany). Subjects were studied in supine position using a
phased-array body coil. Short- and long-axis cine MRI was
performed using an electrocardiogram-triggered cine gradi-
ent echo two-dimensional sequence. Slice thickness was 8
mm, interslice gap 2 mm, using a breathhold technique in
end-expiratory position with a repetition time of 100 ms, an
echo delay time of 4.8 ms, and a flip angle of 30°. For
functional analysis, all short-axis slices from the base to the
apex were analyzed using Argus software, version VB31B
(Siemens, Erlangen, Germany) as previously described
(25,26). The following parameters were determined: LV
end-diastolic volume (EDV) (in ml), LV end-systolic vol-
ume (ESV) (in ml), LV EF (in %), and LV mass (in g).
31P-MRS. The 31P-MRS measurements were performed
on the same 1.5-T scanner using the SLOOP technique as
recently described (22). Briefly, patients were positioned in
prone position on a commercially available, double resonant
31P/1H-surface coil to reduce breathing artifacts. For abso-
lute quantification, an external reference containing 20 ml
3.4 M phenyl phosphonic acid was placed below the coil.
Anatomic information was obtained acquiring short-axis
1H-images with a two-dimensional gradient echo sequence
technique (field of view 400  400 mm2, 30 contiguous
slices, slice thickness 8 mm). After an automatic phase-
sensitive map-shim, a phosphorus-31 three-dimensional
chemical shift imaging sequence was started (double-
oblique orientation, field of view 400 400 320 mm3, 16
 16  8 phase encoding steps). To increase the signal-to-
noise ratio, nuclear Overhauser enhancement was employed
(27). Total examination time ranged from 45 to 60 min,
depending on the heart rate. A Sun Sparc Station 20 (Sun
Microsystems, Grasbrunn, Germany) was used for postpro-
cessing as previously described (22). The short-axis images
were manually segmented. Briefly, the SLOOP program
was run to reconstruct local spectra, taking into account the
B1-field strength, the flip angle, and standard T1 values
(28). The resonance amplitudes in the local spectra were
fitted using the advanced method for accurate, robust, and
efficient spectral fitting (29). The amplitude of the reso-
nance of gamma ATP was taken as the value for ATP. In
addition, nuclear Overhauser enhancement effects were
considered as previously described (23). Owing to the
optimal adaptation of voxel shape to anatomic regions, no
blood correction was necessary. The localization criterion of
Abbreviations and Acronyms
ATP  adenosine triphosphate
AVD  aortic valve disease
DCM  dilated cardiomyopathy
EDV  end-diastolic volume
EF  ejection fraction
ESV  end-systolic volume
HHD  hypertensive heart disease
LV  left ventricle/ventricular
MRI  magnetic resonance imaging
NYHA  New York Heart Association
PCr  phosphocreatine
31P-MRS  phosphorus-31 magnetic resonance
spectroscopy
SLOOP  spatial localization with optimum
pointspread function
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the compartment “LV myocardium” was calculated for
contamination from blood or chest wall for every examina-
tion as described (22).
Statistics. All data are presented as mean  SD. For
statistical analysis, analysis of variance was used to test for
differences among all groups of subjects. Where analysis of
variance indicated significant group differences, Scheffe´ F
test was then used to test for differences between individual
groups, and a p value of 0.05 was considered statistically
significant.
RESULTS
Myocardial function and mass. Left ventricular volumes
and mass of volunteers and patients are summarized in
Table 1. In volunteers, measurements were in agreement
with previously published values (25,26,30). Left ventricular
EDV and ESV were unchanged in patients with HHD and
aortic valve disease (AVD) but were significantly elevated in
DCM (3.3-fold for EDV and 8.8-fold for ESV compared
with volunteers). This clearly demonstrates that substantial
LV dilation occurred in DCM but not in the other groups
of patients. For all groups, stroke volume and cardiac
output, studied under resting conditions, were normal,
attesting to the fact that all patients were compensated at
rest. Left ventricular EF (69  6% in volunteers) was
normal in patients with HHD and tended to be reduced in
AVD. In DCM, a substantial reduction of EF was found
(18  6%), attesting to severe LV dysfunction. Left ven-
tricular mass was significantly increased in all patient groups
(by 55%, 79%, and 68% for HHD, AVD, and DCM,
respectively), demonstrating the presence of LV concentric
(HHD, AVD, unchanged LV volumes) and eccentric
(DCM, increased LV volumes) hypertrophy.
Cardiac high-energy phosphate metabolism. Representa-
tive 31P-SLOOP MRS spectra are shown in Figure 1. The
line width of PCr peaks was comparable in all four groups
(data not shown). Figure 2 demonstrates individual and
mean values for absolute concentrations of PCr and ATP as
well as for PCr/ATP ratios. In volunteers, the PCr concen-
tration was 8.8  1.3 mmol/kg heart weight, ATP was 5.7
 1.0 mmol/kg, and PCr/ATP ratios were 1.59  0.33.
Intrasubject variability was 4.8% and 7.0% for PCr and
ATP, respectively. In patients with HHD, PCr and ATP
concentrations as well as PCr/ATP ratios remained at
normal levels. In patients with aortic stenosis, PCr concen-
trations (by 28%; 6.3  1.5 mmol/kg; p  0.05 vs.
volunteers) were significantly reduced, whereas PCr/ATP
ratios (1.30  0.20) and ATP concentrations (4.9  0.9
mmol/kg) showed a trend for a reduction (by 19% and 14%,
respectively). In patients with DCM, a highly significant
reduction of PCr concentrations (by 51%; 4.3  1.2; p 
0.005 vs. volunteers) was recorded. Furthermore, myocar-
dial ATP concentrations were also found to be significantly
reduced, on average by 35% (3.7 0.5 mmol/kg; p 0.017
vs. volunteers). On the other hand, the observed decrease of
the PCr/ATP ratio (by 25%) was of borderline statistical
significance (p  0.06 vs. volunteers).
Correlations among cardiac function, clinical status, and
energetics. Figure 3 shows correlations among functional
and energetic variables. Left ventricular EF correlated sig-
nificantly with PCr, ATP, and PCr/ATP ratios, but the
closest relationship was found for PCr and the weakest for
PCr/ATP ratios. The same pattern was observed for the
correlation of EDV and ESV (PCr: r0.69, p 0.0001;
ATP: r  0.56, p  0.001; PCr/ATP: r  0.43, p 
0.01) with the three energetic parameters. The correlations
of LV mass and energetic parameters were generally weaker
than those of energetics and volumes/EF, with PCr con-
centrations showing the highest (r  0.46, p  0.01),
PCr/ATP intermediate (r  0.37, p  0.017), and ATP
the lowest, in fact nonsignificant, correlation (r  0.31, p 
0.053). Thus, absolute concentrations showed closer corre-
lations with indices of cardiac dysfunction and dilation than
PCr/ATP ratios. Furthermore, LV mass was not a strong
predictor of changes in absolute or relative levels of cardiac
high-energy phosphates.
For subjects in NYHA functional classes 0 (volunteers
and hypertension), II, and III, PCr levels were 8.38  1.54,
6.78  1.11 (p  0.05 NYHA II vs. III), and 4.23  1.01
(p 0.05 NYHA II or III vs. NYHA 0), respectively; ATP
levels were 5.63  1.04, 5.03  0.81 (p  0.05 NYHA II
vs. III), and 3.58  0.64 (p  0.05 NYHA III vs. NYHA
0), respectively; and PCr/ATP ratios were 1.57 0.34, 1.36
 0.22, and 1.21  0.30 (p  0.05 NYHA III vs. NYHA
0), respectively. Thus, energetic variables also correlated
with the clinical status.
DISCUSSION
In the present report, we demonstrate that absolute myo-
cardial concentrations of PCr are reduced in patients with
aortic stenosis and that absolute concentrations of both PCr
and ATP are decreased in DCM. Furthermore, both PCr
and ATP concentrations correlated significantly with LV
volumes, EF, and clinical status.
Volunteers. In volunteers, cardiac volumes and masses
were all within the range reported previously for larger
Table 1. LV EDV, ESV, SV, CO, EF, Mass and Heart Rate in
Volunteers, Patients with HHD, AVD, and DCM
VOL HHD AVD DCM
LV EDV (ml) 102  15 117  27 128  39 336  76*
LV ESV (ml) 31  10 39  11 53  30 274  76*
LV SV (ml) 71  8 78  20 74  17 68  18
CO (l/min) 4.9  0.9 5.2  1.4 5.8  1.3 5.2  2.0
LV EF (%) 69  6 67  6 60  11 18  6*
LV mass (g) 140  24 217  68* 250  41* 235  46*
Heart rate (beats/min) 75  14 74  10 81  17 92  15
All data presented as mean  SD. *p  0.01 control (VOL) versus patient groups
(HHD, AVD, DCM).
AVD  aortic valve disease; CO  cardiac output; DCM  dilated cardiomy-
opathy; EDV  end-diastolic volume; EF  ejection fraction; ESV  end-systolic
volume; HHD  hypertensive heart disease; LV  left ventricular; SV  stroke
volume; VOL  volunteers.
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groups of normal subjects (25,26). Using SLOOP, we
determined the PCr concentration as 8.8  1.3 mmol/kg
heart weight and ATP as 5.7  1.0 mmol/kg. Previous
MRS studies of volunteers reported PCr values ranging
between 7.9 and 13.5 mmol/kg heart weight and ATP
values ranging from 4.8 to 8.2 mmol/kg (20–22,31,32). The
measurements reported for intrastudy variability using
SLOOP here are based on a small volunteer group. Never-
theless, the values reported compare favorably with the only
previous report on intrasubject variability using quantitative
MRS methods (31) (4% to 7% vs. 18% to 25% for PCr and
ATP). The lower variability of PCr values compared with
ATP is most likely due to the increased signal-to-noise ratio
of PCr amplitudes.
HHD. In the patients with long-standing hypertension,
substantial LV hypertrophy was present, as attested to by a
55% increase in myocardial mass, but LV EF and volumes
were normal. Previously, Okada et al. (31) reported on eight
patients with HHD and, in agreement with our findings,
found that PCr/ATP ratios as well as absolute levels of PCr
and ATP remained unchanged. On the other hand, Lamb
et al. (16) found PCr/ATP ratios in hypertensive patients to
be reduced by 14% and 18% both at rest and during exercise,
respectively. Whether in human HHD, PCr concentrations
remain at normal levels or are slightly reduced, our data
indicate that, in human myocardium, significant LV hyper-
trophy is not always associated with reduced PCr content.
Aortic stenosis. In patients with aortic stenosis, substantial
LV hypertrophy was present with a 79% increase in myo-
cardial mass, whereas LV volumes and EF were still
unchanged. Phosphocreatine levels were reduced by 28%;
ATP levels (14%) only showed a trend for a reduction.
Absolute levels of high-energy phosphates in aortic stenosis
have previously been examined using only invasive myocar-
dial biopsy measurements. Here, significant changes of
high-energy phosphates as well as of total creatine content
have been reported (33–35). In the present study, PCr/ATP
ratios (19%) showed a trend for reduction, which did not
reach statistical significance. Previous studies demonstrated
reductions of PCr/ATP ratios in patients with AVD.
However, patients with more severe, decompensated stages
were included in these studies (11,14,36). Using quantita-
tive MRS techniques, analysis of absolute PCr levels allows
one to detect significant changes of energy metabolism even
Figure 1. 31P-spatial localization with optimum pointspread function spectra obtained from left ventricular myocardium. (a) Healthy volunteer; (b)
hypertensive heart disease; (c) aortic valve disease; (d) dilated cardiomyopathy. Concentrations for phosphocreatine (PCr) and adenosintriphosphate (ATP)
and PCr/ATP ratios were as follows: (a) 9.4, 5.7, 1.65; (b) 9.5, 6.0, 1.58; (c) 5.9, 4.5, 1.31; (d) 2.8, 2.6, 1.08.
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when LV function is still preserved. It is intriguing, and the
reasons remain unclear, why, for a similar extent of myo-
cardial hypertrophy, energetic changes do (aortic stenosis)
or do not (HHD) occur in human myocardium, resulting in
a poor correlation of LV mass and cardiac energetics. The
mechanisms behind these differential responses of human
cardiac energetics to different types of myocardial hypertro-
phy clearly necessitate further study.
Heart failure/DCM. In patients with DCM, severe sys-
tolic dysfunction was attested to by a decrease of LV EF to
18  6%, and several-fold increases of LV ESV and EDV,
while a 68% increase of LV mass indicated eccentric LV
hypertrophy. Previous MRS studies of absolute concentra-
tions in human heart failure are unavailable, but a number of
reports have examined high-energy phosphates in biopsies
taken from patients with DCM. Nascimben et al. (18)
found total creatine levels to be reduced by 51% in agree-
ment with the reduction of PCr levels by 51% in our own
observations. Reductions of ATP levels by 39% (35% in our
study) have been observed (37). Only one previous study
(38) found no change of ATP levels in failing human
myocardium, but in that study absolute ATP levels were low
for both volunteers and patients. Moreover, Bashore et al.
(39) found significant linear correlations between ATP
levels and indices of systolic and diastolic function. Exper-
imental studies (40), analyzing changes of high-energy
phosphate metabolism during development of heart failure,
observed progressive reductions of both ATP (by up to
20%) and total creatine content (by up to 41%). Thus, our
data allow us to make two important observations: 1) in
severe heart failure due to DCM, absolute ATP concentra-
tions are significantly reduced; and 2) because simultaneous
reductions of both ATP and PCr occur, the PCr/ATP ratio,
measured by “conventional” MRS, significantly underesti-
mates true changes of PCr concentrations in heart failure, in
our study by 26%.
Study limitations. Spatial localization with optimum
pointspread function determines high-energy phosphate
concentrations in relation to myocardial mass. The bio-
chemically relevant denominator would be total cardiomy-
ocyte volume. Intuitively, it is unlikely, that the observed
magnitude of changes of PCr and ATP concentrations in
heart failure is due to decreases in cardiomyocyte volume,
but unfortunately, current literature data are unavailable on
quantification of total cardiomyocyte volume fraction in
human cardiac hypertrophy and failure. Previous experi-
mental studies using other MRS methodologies have shown
agreement of in vivo MRS and in vitro biopsy measure-
ments. For the SLOOP method, such experimental valida-
tion is still outstanding. Importantly, however, the deter-
mined values for volunteers are in close agreement with
published biopsy measurements (4,22).
Also, one should be aware that thinner myocardial walls
may lead to systematically different partial volume effects, in
particular in patients with DCM compared with normal
volunteers. As SLOOP determines the localization crite-
rion, the maximum contamination by other compartments
can be analyzed. When we performed this analysis, no
significant differences for contamination by chest wall mus-
cle or chamber blood were found between volunteers and
the three patients groups (data not shown). Otherwise the
Figure 2. Absolute and relative concentrations of phosphocreatine (PCr)
and adenosine triphosphate (ATP) in volunteers (VOL) and in patients
with hypertensive heart disease (HHD), aortic valve disease (AVD), and
dilated cardiomyopathy (DCM). Individual as well as mean  SD values
are shown for each group. Analysis of variance results were as follows: PCr:
VOL vs. HHD p  0.85, VOL vs. AVD p  0.01*, VOL vs. DCM p 
0.000001*; HHD vs. AVD p  0.04*, HHD vs. DCM p  0.00001*,
AVD vs. DCM p 0.03*. ATP: VOL vs. HHD p 0.96, VOL vs. AVD
p  0.29, VOL vs. DCM p  0.0003*; HHD vs. AVD p  0.58, HHD
vs. DCM p  0.002*, AVD vs. DCM p  0.052. PCr/ATP ratio: VOL
vs. HHD p  0.99, VOL vs. AVD p  0.26, VOL vs. DCM p  0.06,
HHD vs. AVD p  0.39, HHD vs. DCM p  0.11, AVD vs. DCM p 
0.89.
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particular phase cancellation properties of the SLOOP
reconstruction may slightly alleviate but certainly not cir-
cumvent this difficulty. This question cannot be fully as-
sessed until a substantially higher spatial resolution is
achievable, for instance at higher magnetic fields.
Although measurement of absolute concentrations of
Figure 3. Correlations among functional and metabolic variables in volunteers (VOL) and in patients with hypertensive heart disease (HHD), aortic valve
disease (AVD), and dilated cardiomyopathy (DCM). Correlations are shown for phosphocreatine (PCr) concentration and adenosintriphosphate (ATP)
concentration, and PCr/ATP ratios with ejection fraction (EF) (left column) and end-diastolic volume (EDV) (right column). Diamonds  VOL;
squares  HHD; triangles  AVD; circles  DCM.
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high-energy phosphate metabolites is a significant step
forward, for a complete causal analysis, we must be able to
measure ATP turnover rates and calculate free ADP con-
centrations and the free energy change of ATP hydrolysis
(delta G) (4,41,42). Therefore, simultaneous measurement
of myocardial total creatine content is required. This may be
achievable by a combination of 31P-MRS and 1H-MRS.
Such measurements will be the focus of our (43) and other
groups’ (e.g., 44) future work, and should finally answer the
question of the true functional role of myocardial high-
energy phosphate metabolism in human heart failure.
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